research communications
A cryoprotectant induces conformational change in glyceraldehyde-3-phosphate dehydrogenase
aDepartment of Herbal Medicine Resources, College of Environmental and Bioresource Sciences, Chonbuk National University, Iksan 54596, Republic of Korea, and bDepartment of Lifestyle, College of Environmental and Bioresource Sciences, Chonbuk National University, Iksan 54596, Republic of Korea
*Correspondence e-mail: nationface@jbnu.ac.kr
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme, catalyses the conversion of D-glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. While mammalian and yeast GAPDHs are multifunctional proteins that have additional functions beyond those involved in glycolysis, including reactions related to nuclear RNA transport, DNA replication/repair, membrane fusion and cellular apoptosis, Escherichia coli GAPDH (ecGAPDH) has only been reported to function in glycolysis. The S-loop of GAPDH is required for interaction with its cofactor and with other proteins. In this study, the three-dimensional of GAPDH treated with trehalose is reported at 2.0 Å resolution. Trehalose was used as a cryoprotectant for the GAPDH crystals. The structure of trehalose-bound ecGAPDH was compared with the structures of both NAD+-free and NAD+-bound ecGAPDH. At the S-loop, the bound trehalose in the GAPDH structure induces a 2.4° rotation compared with the NAD+-free ecGAPDH structure and a 3.1° rotation compared with the NAD+-bound ecGAPDH structure.
Keywords: crystal structure; glyceraldehyde-3-phosphate dehydrogenase; GAPDH; cryoprotectants; trehalose.
PDB reference: glyceraldehyde-3-phosphate dehydrogenase, 5za0
1. Introduction
Many crystals of biological macromolecules are sensitive to X-rays near room temperature and frequently suffer from radiation damage, especially when X-ray experiments are carried out on highly intense synchrotron beamlines (Hope, 1990). To prevent radiation damage from X-rays (Watenpaugh, 1991; Rodgers, 1994; Low et al., 1966) and to facilitate the transport and simple storage of protein crystals, many cryoprotectants have been developed (Garman, 1999, 2003) and many cryoprotectant products are commercially available, such as CryoPro from Hampton Research.
In general, cryoprotectants are small polyols and organics, such as glycerol, ethylene glycol, 1,2-propanediol, diethylene glycol, 2-methyl-2,4-pentanediol, dimethyl sulfoxide or other nonvolatile ). Low-molecular-weight polyethylene (PEGs), such as PEG 200 or PEG 400, are suitable cryoprotectants in many cases. Higher molecular-weight PEGs can also be used, albeit with more difficulty than lower molecular-weight PEGs. High concentrations of salts, such as lithium formate (Rubinson et al., 2000), or such as malonate, can also be used (Holyoak et al., 2003), as can sugars such as sucrose, trehalose, sorbitol, xylitol or glucose (Pflugrath, 2015).
(Pflugrath, 2015Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is an enzyme that catalyses the conversion of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate using NAD+ as a cofactor (Baker et al., 2014) and is known to be a moonlighting protein (Savreux-Lenglet et al., 2015). This enzyme plays multiple roles in the regulation of stability (Zhou et al., 2008), intracellular membrane trafficking (Sirover, 2012), iron uptake and transport (Zaid et al., 2009), DNA replication and repair (Zheng et al., 2003), and nuclear RNA transport (Dastoor & Dreyer, 2001). In particular, yeast GAPDH is inhibited by trehalose (Araiza-Olivera et al., 2010). An important region of GAPDH is the S-loop (residues 178–201), a long, winding region of the enzyme that is known to interact with some proteins (Kosova et al., 2017; Duée et al., 1996). The S-loop region of NAD+-free GAPDH has a very flexible shape and thus does not show clear electron density (Ferreira-da-Silva et al., 2006; Querol-García et al., 2017). On the other hand, in NAD+-bound GAPDH S-loop fixation occurs by the formation of a complex with the coenzyme NAD+ (Kitatani et al., 2006).
GAPDHs have been isolated from bacteria, archaea, prokaryotes, eukaryotes, plants and mammals. Under normal cellular conditions, GAPDH primarily has a tetrameric conformation composed of four identical 35 kDa subunits (Nicholls et al., 2012; Frayne et al., 2009). GAPDH consists of an NAD+-binding domain (residues 2–148 and 312–330), which is composed of α/β dinucleotide-binding folds or Rossmann folds, and a (residues 149–311), which is composed of eight antiparallel β-sheets with an α-helix and several short loops (Duée et al., 1996; Yun et al., 2000). The activity of GAPDH requires the binding of NAD+.
In this study, the purification, crystallization and cryoprotection of Escherichia coli GAPDH (ecGAPDH) and the three-dimensional structure of trehalose-bound ecGAPDH are described. The GAPDH crystals were cryoprotected with a solution containing 15% of the disaccharide trehalose.
2. Materials and methods
2.1. Preparation of GAPDH
E. coli BL21 (DE3) cells were grown on LB agar medium containing 100 µM ampicillin. A single colony was cultivated in 100 ml LB medium overnight at 37°C. The next day, a main culture was cultivated in 1 l LB medium for 4 h at 37°C. The cultured cells were harvested by centrifugation (4°C, 8000 rev min−1, 5 min). The harvested cells were resuspended in buffer A (20 mM Tris, 130 mM NaCl pH 7.5). The cells were disrupted by sonication on ice and the cell lysate was then separated from the cell debris by centrifugation (4°C, 20 000 rev min−1, 20 min). The supernatant was loaded onto a HisTrap column (5 ml; GE Healthcare, Little Chalfont, England) that had been equilibrated with buffer A. The column was washed with buffer A and the proteins bound to the HisTrap column were eluted with buffer B (20 mM Tris, 130 mM NaCl, 0.2 M imidazole pH 7.5). The extracted active proteins, including ecGAPDH, were loaded onto a HiTrap heparin column (5 ml; GE Healthcare) equilibrated with buffer A (Reisz et al., 2016). After washing the column with buffer A, buffer C (20 mM Tris pH 7.5, 1 M NaCl) was gradually applied as an elution buffer. ecGAPDH was eluted at concentrations of 200–300 mM NaCl and was dialysed thoroughly against buffer A.
2.2. Crystallization
Purified ecGAPDH was concentrated to 20 mg ml−1 using Amicon filters (30 kDa cutoff; Sigma–Aldrich, St Louis, Missouri, USA). Concentrated ecGAPDH (2 µl) was mixed with reservoir solution (2 µl) consisting of 2.8 M ammonium sulfate, 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) pH 5.5–6.5 at 4°C. GAPDH crystals grew within two weeks using the hanging-drop method. X-ray data were collected from GAPDH crystals treated with a cryoprotectant consisting of 15%(v/v) trehalose at 100 K. Crystallization information is given in Table 1.
|
2.3. Data collection and processing
X-ray diffraction data were collected on beamline 7A at the Pohang Accelerator Laboratory (PAL 7A SB I; Pohang, Republic of Korea) using a CCD detector (ADSC Quantum 270) at an X-ray wavelength of 1.0 Å. All images were indexed, integrated and scaled using the XDS program package and the CCP4 program SCALA. The crystals belonged to the tetragonal I4122, with unit-cell parameters a = 121.29, b = 121.29, c = 156.06 Å, α = 90, β = 90, γ = 90°. Data-collection and processing statistics are given in Table 2.
|
3. and refinement
Initial phases for GAPDH were obtained by a conventional molecular-replacement protocol (rotation, translation and rigid-body fitting) using the structure of E. coli GAPDH (PDB entry 1s7c; Berkeley Structural Genomics Center, unpublished work) as an initial search model. The model was fitted more appropriately by simulated annealing in CNS. Manual rebuilding of the GAPDH model and electron-density interpretation were performed after each cycle using Coot (Emsley et al., 2010). Restrained, individual B factors were refined and the was finalized using the CCP4 program REFMAC5 and other programs in the CCP4 suite (Winn et al., 2011). GAPDH was modelled with TLS using anisotropic temperature factors for all atoms. The final model had Rfree and Rcryst factors of 20.5% and 18.4%, respectively (Table 3). Structure validation was performed with SFCHECK (Vaguine et al., 1999), PROCHECK (Laskowski et al., 1996) and ADIT (Bhat et al., 2001). DynDom, a program that determines domain movement and relative inter-domain rotation angles in proteins for which two conformations are available, was used to study domain rotation (Poornam et al., 2009; Hayward et al., 1997). Coordinates have been deposited in the Protein Data Bank with accession code 5za0.
|
4. Results and discussion
GAPDH was purified from E. coli without any genetic manipulation. Despite the use of a nonrecombinant gene, GAPDH could surprisingly be purified using a HisTrap column. Approximately 2 mg of purified ecGAPDH was obtained from a 1 l culture. For crystallization purposes, ecGAPDH was concentrated to approximately 20 mg ml−1 using an Amicon concentrator (30 kDa cutoff; Sigma–Aldrich). Although ecGAPDH was stable at room temperature, crystals suitable for X-ray analysis were grown by the hanging-drop method at 4°C (Fig. 1). Tetragonal bipyramidal crystals appeared within two weeks and grew for a further week. For data collection, the crystals were cryoprotected with 15% trehalose. In the X-ray studies, a single crystal of ecGAPDH was mounted in a cryoloop. The crystals showed significant overloads. Thus, even when the resolution was reduced, X-ray diffraction was measured at 80% attenuation. Nevertheless, these crystals diffracted to 2.0 Å resolution on PAL 7A SB I (Supplementary Fig. S1).
The structure was solved by E. coli GAPDH structure (PDB entry 1s7c) as a starting model. was performed using Phaser from the CCP4 suite. The final ecGAPDH model had Rfree and Rcryst factors of 20.5% and 18.4%, respectively. The solved structure had a monomer in the The monomer contained 330 residues, one sulfate ion, one trehalose molecule and 171 water molecules. The number of water molecules in the current GAPDH structure is restricted despite the high resolution and low mosaicity. To study the conformational changes induced by the binding of trehalose to ecGAPDH, a detailed structural comparison of trehalose-free and trehalose-bound GAPDH was performed.
using theA list of commonly used sugar cryoprotectants is shown in Supplementary Table S1. Among them, ecGAPDH and glycerol was not found, even though glycerol has previously been reported to be bound in GAPDH structures (Mukherjee et al., 2010; Cook et al., 2009; Robien et al., 2006; Chaikuad et al., 2011; Querol-García et al., 2017; Moreau et al., 2017). Only the GAPDH structure with trehalose was significantly different from published structures.
such as sucrose, maltose and trehalose have been used to cryoprotect GAPDH crystals. Glycerol, a commonly used cryoprotectant, has also been used in a comparison with sugar-protected GAPDH. Mixtures of 30% glycerol and 15% sugars were used for cryoprotection. None of the resulting crystals exhibited any signs of cracking or melting during treatment with the cryoprotectants. The crystals obtained using glycerol as a cryoprotectant showed a resolution of 2.1 Å. The crystals obtained using sucrose and maltose showed resolutions of 2.4 and 2.2 Å, respectively. The crystals obtained using trehalose showed a resolution of 2.0 Å. Although sucrose and maltose have similar structures to that of trehalose, these sugars did not bind toAn electron-density map clearly indicated ordered trehalose molecules bound to the protein. One trehalose molecule bound to ecGAPDH in the S-loop region (Fig. 2). As described above, the S-loop region of GAPDH without NAD+ bound as a cofactor is very flexible and does not exhibit definite electron density (Querol-García et al., 2017). Despite the absence of NAD+, trehalose stabilized the S-loop of the enzyme. As a result, the electron-density map of the S-loop region of the protein was clear. The rotation angle and the relative rotation angle between the NAD+-binding domain and the were measured. The GAPDH molecule shows a rotation of approximately 2.4–3.1° when superpositioned on the NAD+-free ecGAPDH (PDB entry 1dc5) and/or the NAD+-bound ecGAPDH (PDB entry 1dc6) structures (Yun et al., 2000; Fig. 3). The inhibition of yeast GAPDH is reportedly proportional to the concentration of trehalose (Araiza-Olivera et al., 2010). The GAPDHs from yeast and E. coli have similar structures. Although ecGAPDH has not been reported to be inhibited by trehalose, trehalose induced a conformational change in ecGAPDH in the current structure. The rotation of GAPDH also induced a conformational change in its active site. This suggests that the binding of trehalose to GAPDH induced a conformational change in its active site to prevent the binding of NAD+, although the NAD+- and trehalose-binding sites differ from one another.
To examine the time dependence of the cryoprotectant effect on GAPDH crystals, the cryoprotectant soaking time was varied from 1 to 10 min and the data for all crystals from each time were evaluated systematically. The GAPDH crystals neither cracked nor melted as a result of the penetration of cryoprotectants into the solvent channels. These results suggested that the conformational changes in GAPDH owing to the binding of trehalose were independent of soaking time for up to 10 min.
Supporting information
PDB reference: glyceraldehyde-3-phosphate dehydrogenase, 5za0
Supplementary Table S1 and Supplementary Figure S1. DOI: https://doi.org/10.1107/S2053230X18004557/ek5003sup1.pdf
Acknowledgements
I am grateful to Pohang Accelerator Laboratory (PAL) where the data were collected on beamline 7A. I thank Chair Professor Dr Hui-Woog Choe at Chonbuk National University and at the Department of Brain and Cognitive Sciences of DGIST, Republic of Korea for fruitful discussions and for continuous support of this work. I also thank Professor Dr Joerg Labahn at the Centre for Structural Systems Biology (CSSB), Deutsches Elektronen-Synchrotron (DESY), Hamburg, Germany for discussions during the early stage of this work.
Funding information
This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), the Ministry of Science, ICT and Future Planning (2015R1C1A1A02037509), research funds for newly appointed professors of Chonbuk National University in 2014, and a grant from the Jeon-Dae Memorial Fund in 2014.
References
Araiza-Olivera, D., Sampedro, J. G., Mújica, A., Peña, A. & Uribe-Carvajal, S. (2010). FEM. Yeast Res. 10, 282–289. CAS Google Scholar
Baker, B. Y., Shi, W., Wang, B. & Palczewski, K. (2014). Protein Sci. 23, 1629–1639. Web of Science CrossRef CAS Google Scholar
Bhat, T. N., Bourne, P., Feng, Z., Gilliland, G., Jain, S., Ravichandran, V., Schneider, B., Schneider, K., Thanki, N., Weissig, H., Westbrook, J. & Berman, H. M. (2001). Nucleic Acids Res. 29, 214–218. Web of Science CrossRef PubMed CAS Google Scholar
Chaikuad, A., Shafqat, N., Al-Mokhtar, R., Cameron, G., Clarke, A. R., Brady, R. L., Oppermann, U., Frayne, J. & Yue, W. W. (2011). Biochem. J. 435, 401–409. Web of Science CrossRef CAS Google Scholar
Cook, W. J., Senkovich, O. & Chattopadhyay, D. (2009). BMC Struct. Biol. 9, 51. Google Scholar
Dastoor, Z. & Dreyer, J. L. (2001). J. Cell Sci. 114, 1643–1653. Web of Science PubMed CAS Google Scholar
Duée, E., Olivier-Deyris, L., Fanchon, E., Corbier, C., Branlant, G. & Dideberg, O. (1996). J. Mol. Biol. 257, 814–838. CrossRef CAS PubMed Web of Science Google Scholar
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta Cryst. D66, 486–501. Web of Science CrossRef CAS IUCr Journals Google Scholar
Ferreira-da-Silva, F., Pereira, P. J., Gales, L., Roessle, M., Svergun, D. I., Moradas-Ferreira, P. & Damas, A. M. (2006). J. Biol. Chem. 281, 33433–33440. Web of Science PubMed CAS Google Scholar
Frayne, J., Taylor, A., Cameron, G. & Hadfield, A. T. (2009). J. Biol. Chem. 284, 22703–22712. Web of Science CrossRef CAS Google Scholar
Garman, E. (1999). Acta Cryst. D55, 1641–1653. Web of Science CrossRef CAS IUCr Journals Google Scholar
Garman, E. (2003). Curr. Opin. Struct. Biol. 13, 545–551. Web of Science CrossRef PubMed CAS Google Scholar
Hayward, S., Kitao, A. & Berendsen, H. J. (1997). Proteins, 27, 425–437. CrossRef CAS PubMed Google Scholar
Holyoak, T., Fenn, T. D., Wilson, M. A., Moulin, A. G., Ringe, D. & Petsko, G. A. (2003). Acta Cryst. D59, 2356–2358. Web of Science CrossRef CAS IUCr Journals Google Scholar
Hope, H. (1990). Annu. Rev. Biophys. Biophys. Chem. 19, 107–126. CrossRef CAS PubMed Google Scholar
Kitatani, T., Nakamura, Y., Wada, K., Kinoshita, T., Tamoi, M., Shigeoka, S. & Tada, T. (2006). Acta Cryst. F62, 727–730. Web of Science CrossRef IUCr Journals Google Scholar
Kosova, A. A., Khodyreva, S. N. & Lavrik, O. I. (2017). Biochemistry, 82, 643–654. CAS Google Scholar
Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. (1996). J. Biomol. NMR, 8, 477–486. CrossRef CAS PubMed Web of Science Google Scholar
Low, B. W., Chen, C. C. H., Berger, J. E., Singman, L. & Pletcher, J. F. (1966). Proc. Natl Acad. Sci. USA, 56, 1746–1750. CrossRef PubMed CAS Web of Science Google Scholar
Moreau, C., Terrasse, R., Thielens, N. M., Vernet, T., Gaboriaud, C. & Di Guilmi, A. M. (2017). J. Biol. Chem. 292, 2217–2225. Web of Science CrossRef CAS Google Scholar
Mukherjee, S., Dutta, D., Saha, B. & Das, A. K. (2010). J. Mol. Biol. 401, 949–968. Web of Science CrossRef CAS PubMed Google Scholar
Nicholls, C., Li, H. & Liu, J.-P. (2012). Clin. Exp. Pharmacol. Physiol. 39, 674–679. Web of Science CrossRef CAS Google Scholar
Pflugrath, J. W. (2015). Acta Cryst. F71, 622–642. Web of Science CrossRef IUCr Journals Google Scholar
Poornam, G. P., Matsumoto, A., Ishida, H. & Hayward, S. (2009). Proteins, 76, 201–212. Web of Science CrossRef CAS Google Scholar
Querol-García, J., Fernández, F. J., Marin, A. V., Gómez, S., Fullà, D., Melchor-Tafur, C., Franco-Hidalgo, V., Albertí, S., Juanhuix, J., Rodríguez de Córdoba, S., Regueiro, J. R. & Vega, M. C. (2017). Front. Microbiol. 8, 541. Google Scholar
Reisz, J. A., Wither, M. J., Dzieciatkowska, M., Nemkov, T., Issaian, A., Yoshida, T., Dunham, A. J., Hill, R. C., Hansen, K. C. & D'Alessandro, A. (2016). Blood, 128, e32–e42. Web of Science CrossRef CAS Google Scholar
Robien, M. A. et al. (2006). Proteins, 62, 570–577. Web of Science CrossRef CAS Google Scholar
Rodgers, D. W. (1994). Structure, 2, 1135–1140. CrossRef CAS PubMed Web of Science Google Scholar
Rubinson, K. A., Ladner, J. E., Tordova, M. & Gilliland, G. L. (2000). Acta Cryst. D56, 996–1001. CrossRef CAS IUCr Journals Google Scholar
Savreux-Lenglet, G., Depauw, S. & David-Cordonnier, M. H. (2015). Int. J. Mol. Sci. 16, 26555–26581. CAS Google Scholar
Sirover, M. A. (2012). J. Cell. Biochem. 113, 2193–2200. Web of Science CrossRef CAS Google Scholar
Vaguine, A. A., Richelle, J. & Wodak, S. J. (1999). Acta Cryst. D55, 191–205. Web of Science CrossRef CAS IUCr Journals Google Scholar
Watenpaugh, K. D. (1991). Curr. Opin. Struct. Biol. 1, 1012–1015. CrossRef CAS Google Scholar
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242. Web of Science CrossRef CAS IUCr Journals Google Scholar
Yun, M., Park, C.-G., Kim, J.-Y. & Park, H.-W. (2000). Biochemistry, 39, 10702–10710. Web of Science CrossRef PubMed CAS Google Scholar
Zaid, H., Talior-Volodarsky, I., Antonescu, C., Liu, Z. & Klip, A. (2009). Biochem. J. 419, 475–484. Web of Science CrossRef CAS Google Scholar
Zheng, L., Roeder, R. G. & Luo, Y. (2003). Cell, 114, 255–266. Web of Science CrossRef PubMed CAS Google Scholar
Zhou, Y., Yi, X., Stoffer, J. B., Bonafe, N., Gilmore-Hebert, M., McAlpine, J. & Chambers, S. K. (2008). Mol. Cancer Res. 6, 1375–1384. Web of Science CrossRef CAS Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.